ImmunityBio initiated Phase 1 trials for NSCLC in US sites, while the FDA remained supportive of new data and the company sought guideline expansion from NCCN.
1 report, 1 independent
Updated Jul 25
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
ImmunityBio initiated Phase 1 trials for NSCLC in US sites, while the FDA remained supportive of new data and the company sought guideline expansion from NCCN.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
ImmunityBio
biotech company
Nothing else this week.
- FDA
-
National Comprehensive Cancer Network
non-profit organization in the USA
Related events
Coverage
Newest first; wire copies grouped- Business WireImmunityBio Reports 60% Increase in Revenue in Q2 2025, with Year-to-Date Sales of $43 Million and 246% Unit Growth Since J-Code with Regulatory Updates CULVER CITY, Calif., July 25, 2025--(BUSINESS